Management focus is on a strong balance sheet
-"After the fairly decent Q3 results and the guidance cut on costs, a mix of lower operating costs, higher interest income (again) and a lower tax rate have all driven an upgrade to our 2023 EPS ..."
You may also be interested by these reports :
Sanofi has unveiled its R&D plans today in an effort to convince investors of their effectiveness, as the share price hasn’t yet fully recovered ...
With the >$3bn Carmot Therapeutics acquisition, Roche has entered the race in the burgeoning anti-obesity market. While, against the backdrop of ...
Takeaways from our third & fourth Materials Reverse Roadshow Day with Sika, Siegfried, Wacker and Bucher
Bayer (Buy, Germany) has entered the Alphavalue top 20 chart of companies with the strongest upsides. Being number 12 in this hit parade, the company ...